Letter from the Editor EditorProf. Gert Ossenkoppele, Amsterdam UMC, the Netherlands ConferenceASH 2022 20 February 2023 13:27
ASH 2022 Highlights Podcast Presented ByRobert van den Heuvel, Medicom ConferenceASH 2022 5 January 2023 02:23
Blinatumomab candidate for standard-of-care in newly diagnosed B-ALL Presented ByProf. Mark Litzow, Mayo Clinic, MN, USA TrialPhase 3, ECOG-ACRIN-E1910 NCTN ConferenceASH 2022 TypePeer-reviewed article 20 February 2023 11:07
High-dose methotrexate or standard interim maintenance in young patients with ALL? Presented ByMs Amy Kirkwood, University College London, UK TrialUKALL 2011 ConferenceASH 2022 TypePeer-reviewed article 20 February 2023 11:01
Excellent results for triplet regimen in FLT3-mutated AML Presented ByProf. Nicholas Short, University of Texas, TX, USA ConferenceASH 2022 TypePeer-reviewed article 20 February 2023 11:25
MRD by qPCR prognostic of outcomes in venetoclax-treated NPM1-mutated AML Presented ByMr Jad Othman, Guy’s and St Thomas’ NHS Foundation Trust, UK ConferenceASH 2022 TypePeer-reviewed article 20 February 2023 11:20
Promising results for triplet therapy with magrolimab in AML Presented ByProf. Naval Daver, Anderson Cancer Center, TX, USA TrialPhase 3, ENHANCE-3 ConferenceASH 2022 TypePeer-reviewed article 20 February 2023 11:17
Should we use intensive chemotherapy prior to allo-HCT in relapsed/refractory AML? Presented ByProf. Matthias Stelljes, University of Muenster, Germany TrialPhase 3, EATL3-ASAP ConferenceASH 2022 TypePeer-reviewed article 20 February 2023 11:13
Zanubrutinib wins battle of BTK inhibitors in relapsed or refractory CLL/SLL Presented ByProf. Jennifer Brown, Dana Farber Cancer Institute, MA, USA TrialPhase 3, ALPINE ConferenceASH 2022 TypePeer-reviewed article 20 February 2023 11:40
Ibrutinib plus venetoclax displays long-term benefits in CLL Presented ByProf. John Allan, Weill Cornell Medicine, NY, USA TrialPhase 2, CAPTIVATE ConferenceASH 2022 TypePeer-reviewed article 20 February 2023 11:28
Talquetamab further investigated in heavily pre-treated MM after promising phase 2 data Presented ByProf. Ajai Chari, Mount Sinai School of Medicine, NY, USA TrialPhase 1/2, MonumenTAL-1 ConferenceASH 2022 TypePeer-reviewed article 20 February 2023 12:19
Promising results of elranatamab for MM in phase 2 MagnetisMM-3 trial Presented ByProf. Nizar Bahlis, University of Calgary, Canada TrialPhase 2, MagnetisMM-3 ConferenceASH 2022 TypePeer-reviewed article 20 February 2023 12:09
Deep and durable responses for quadruple therapy in smouldering MM Presented ByProf. Shaji Kumar, Mayo Clinic, MN, USA TrialPhase 2, ASCENT ConferenceASH 2022 TypePeer-reviewed article 20 February 2023 12:04
Ultra-sensitive MRD assessment in MM with BloodFlow Presented ByDr Laura Notarfranchi, University of Parma, Italy TrialPhase 3, GEM2014MAIN ConferenceASH 2022 TypePeer-reviewed article 20 February 2023 11:55
CAR-Hematotox score proves useful in relapsed/refractory MM Presented ByDr Kai Rejeski, LMU Munich, Germany ConferenceASH 2022 TypePeer-reviewed article 20 February 2023 11:52
Head-to-head: VMP versus Rd in transplant-ineligible MM Presented ByDr Sara Bringhen, Università degli Studi di Torino, Italy TrialPhase 4, REAL-MM ConferenceASH 2022 TypePeer-reviewed article 20 February 2023 11:47
Ibrutinib added to ASCT improves clinical outcomes in mantle cell lymphoma Presented ByProf. Martin Dreyling, University Hospital Munich, Germany TrialPhase 3, Triangle ConferenceASH 2022 TypePeer-reviewed article 20 February 2023 12:39
High-dose chemotherapy plus ASCT superior to standard immuno-chemotherapy in primary CNS lymphoma Presented ByProf. Gerald Illerhaus, Klinikum Stuttgart, Germany TrialPhase 3, MATRix/IELSG43 ConferenceASH 2022 TypePeer-reviewed article 20 February 2023 12:37
Odronextamab has considerable anti-tumour effects in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma Presented ByProf. Won-Seog Kim, Samsung Medical Center, South Korea TrialPhase 2, ELM-2 trial ConferenceASH 2022 TypePeer-reviewed article 20 February 2023 12:30
Excellent results for AFM13-complexed NK cells in CD30-positive lymphoma Presented ByDr Yago Nieto, University of Texas, TX, USA ConferenceASH 2022 TypePeer-reviewed article 20 February 2023 12:27
CAR-Hematotox score predicts toxicity, infections, and clinical outcomes in MCL Presented ByDr Kai Rejeski, LMU Munich, Germany ConferenceASH 2022 TypePeer-reviewed article 20 February 2023 12:23
Efgartigimod successful in immune thrombocytopenia Presented ByProf. Catherine Broome, Georgetown University, Washington DC, USA TrialPhase 3, ADVANCE ConferenceASH 2022 TypePeer-reviewed article 20 February 2023 12:57
INCA033989: novel investigational agent for CALR-mutated MPN Presented ByDr Edimara Reis, Incyte Corporation, DE, USA ConferenceASH 2022 TypePeer-reviewed article 20 February 2023 12:47
Ruxolitinib mediates clonal evolution of RAS pathway mutations in MPN Presented ByDr Nabih Maslah, Université Paris Cité, France ConferenceASH 2022 TypePeer-reviewed article 20 February 2023 12:43
Long-term risk for haematologic disease in persistent, isolated mild thrombocytopenia Presented ByDr Nardeen Ayad, Massachusetts General Hospital, MA, USA ConferenceASH 2022 TypePeer-reviewed article 20 February 2023 12:50
C1 inhibitor deficiency linked to thrombosis Presented ByDr Steven Grover, University of North Carolina, NC, USA ConferenceASH 2022 TypePeer-reviewed article 20 February 2023 13:18
Durable responses to gene therapy in haemophilia A Presented ByProf. Stacy Croteau, Harvard Medical School, MA, USA TrialPhase 1/2, SPK-8011 ConferenceASH 2022 TypePeer-reviewed article 20 February 2023 13:16
Long-term benefits from beti-cel in transfusion-dependent β-thalassaemia Presented ByProf. Mark Walters; Prof. Franco Locatelli TrialLTF-303 ConferenceASH 2022 TypePeer-reviewed article 20 February 2023 13:14
Neutrodiet: non-restricted diet is the preferred option after SCT Presented ByProf. Federico Stella, Università degli Studi di Milano, Italy ConferenceASH 2022 TypePeer-reviewed article 20 February 2023 13:11
Iptacopan offers solution for patients with PNH and residual anaemia after standard-of-care Presented ByProf. Régis de Latour, Saint-Louis Hospital, France TrialPhase 3, Apply-PNH ConferenceASH 2022 TypePeer-reviewed article 20 February 2023 13:09
Novel therapy may replace standard-of-care prophylaxis for GVHD Presented ByProf. Shernan Holtan, University of Minnesota, MN, USA TrialPhase 3, BMT CTN 1703 ConferenceASH 2022 TypePeer-reviewed article 20 February 2023 13:05
LMWH does not result in higher live birth rates in women with inherited thrombophilia Presented ByProf. Saskia Middeldorp, Radboud UMC, the Netherlands TrialALIFE2 ConferenceASH 2022 TypePeer-reviewed article 20 February 2023 13:01